Oxford Biomedica (OXB) is a global, quality- and innovation-led CDMO specializing in viral vector development and manufacturing for cell and gene therapy. With 25+ years of experience, OXB is the first and currently only FDA-approved CDMO for commercial production of lentiviral vectors for CAR-T therapy. The company operates GMP suites across three countries with extensive end-to-end capabilities in lentivirus, AAV, and adenovirus vectors.
Viral vector CDMO with proprietary LentiVector and inAAVate platforms. End-to-end capabilities from plasmid design and optimization through clinical and commercial GMP manufacturing. First commercial supplier of lentiviral vectors for a CAR-T therapy. Strong regulatory track record with 150+ successful audits.
3 sites worldwide
Involvement in 2 clinical trials
No reviews available yet.
No documents available.